Core business revenue rose 85% year-over-year, driven by PFAS and Healthcare, while group sales dipped due to lower subsidiary performance. Cost reductions improved EBITDA and liquidity, with a successful rights issue supporting operations into 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.